DKS Co. Ltd.
【Daiichi Industrial Pharmaceuticals】2026 Financial Results ｜ Sales of ¥82.8 billion (YoY 13.1% increase)
Daiichi Industrial Pharmaceuticals' fiscal year 2026 financial results show sales of ¥82.8 billion (up 13.1% YoY), net profit of ¥6.1 billion (up 138.6%), reaching record highs. Segments such as Electronics & Information and Environment & Energy expanded significantly, contributing to profit growth.
Key Figures
- Net Sales: ¥82.886 billion (up 13.1% YoY)
- Net Income Attributable to Owners of Parent: ¥6.169 billion (up 138.6%)
- Dividend: ¥90 (increase)
AI要約
Performance Overview
Daiichi Industrial Pharmaceuticals' fiscal year 2026 financial results recorded a new high with net sales of ¥82.886 billion (up 13.1% YoY), operating income of ¥10.17 billion (up 88.9%), and net income of ¥6.169 billion (up 138.6%). Segment-wise, Electronics & Information and Environment & Energy saw significant growth, successfully expanding sales of high-value-added products and improving profit margins. Assets such as fixed assets and investment securities also increased, indicating a solid financial position.
Future Outlook and Impact on Shareholders
The company is in the second year of its medium-term management plan 'SMART 2030', targeting sales of ¥84 billion and net profit of ¥6.7 billion. While there are risks of increased costs due to rising crude oil and naphtha prices and geopolitical tensions in the Middle East, efforts are underway to diversify procurement sources and appropriately reflect pricing adjustments in sales. The planned annual dividend is ¥150, aiming to achieve stable profit returns and growth investments.
Daiichi Industrial Pharmaceuticals Co., Ltd.
Company overview · Stock price · Financial data · All IR
